Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Gross Margin (2016 - 2025)

Amicus Therapeutics' Gross Margin history spans 10 years, with the latest figure at 85.67% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 442.0% year-over-year to 85.67%, compared with a TTM value of 88.5% through Dec 2025, down 148.0%, and an annual FY2025 reading of 88.5%, down 148.0% over the prior year.
  • Gross Margin for Q4 2025 was 85.67% at Amicus Therapeutics, down from 88.49% in the prior quarter.
  • The five-year high for Gross Margin was 91.95% in Q1 2023, with the low at 83.55% in Q3 2022.
  • Average Gross Margin over 5 years is 89.28%, with a median of 90.16% recorded in 2023.
  • Year-over-year, Gross Margin soared 684bps in 2023 and then crashed -442bps in 2025.
  • Tracing FOLD's Gross Margin over 5 years: stood at 90.44% in 2021, then decreased by -1bps to 89.35% in 2022, then grew by 1bps to 90.16% in 2023, then fell by 0bps to 90.09% in 2024, then decreased by -5bps to 85.67% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Gross Margin are 85.67% (Q4 2025), 88.49% (Q3 2025), and 90.16% (Q2 2025).